Key figures as of March 31, 2017

 

Cash, cash equivalents and financial assets*

€223.8m

* Including short term investments and non-current financial instruments

Financial debt

€5.0m


Staff

166 employees, 3/4 of whom are dedicated to R&D


Portfolio

7 programs in development:

  • 3 programs in clinical trials including one licensed to Bristol-Myers Squibb and one partnered with AstraZeneca
  • 4 proprietary preclinical programs

See FY financial results for 2016